[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MA42006A1 - Molécules hybrides - Google Patents

Molécules hybrides

Info

Publication number
MA42006A1
MA42006A1 MA42006A MA42006A MA42006A1 MA 42006 A1 MA42006 A1 MA 42006A1 MA 42006 A MA42006 A MA 42006A MA 42006 A MA42006 A MA 42006A MA 42006 A1 MA42006 A1 MA 42006A1
Authority
MA
Morocco
Prior art keywords
hybrid molecules
applications
pyochelin
inhibit
growth
Prior art date
Application number
MA42006A
Other languages
English (en)
Inventor
Christian Lange
Carsten Corvey
Heike Stump
Jochen Kruip
Bernhard Calandra
Astrid Rey
Michael Mourez
Laurent Fraisse
Christine Rothe
Andrea Allersdorfer
Alexander Wiedenmann
Marlon Hinner
Bradley Lunde
Kristian Jensen
Martin Hülsmeyer
Ingo Focken
Dorothea Rat
Thomas Stuedemann
Hans-Falk Rasser
Juergen Schaefer
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA42006A1 publication Critical patent/MA42006A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des molécules hybrides qui présentent une spécificité de liaison pour la pyoverdine de type i, ii et iii et la pyochéline et peuvent être utilisées dans diverses applications, y compris des applications diagnostiques et/ou thérapeutiques, par exemple, pour inhiber ou réduire la croissance de
MA42006A 2015-07-07 2016-07-06 Molécules hybrides MA42006A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15306106.4A EP3115371A1 (fr) 2015-07-07 2015-07-07 Molécules de fusion
PCT/EP2016/065899 WO2017005763A1 (fr) 2015-07-07 2016-07-06 Molécules hybrides

Publications (1)

Publication Number Publication Date
MA42006A1 true MA42006A1 (fr) 2018-09-28

Family

ID=53719726

Family Applications (1)

Application Number Title Priority Date Filing Date
MA42006A MA42006A1 (fr) 2015-07-07 2016-07-06 Molécules hybrides

Country Status (26)

Country Link
US (2) US10316071B2 (fr)
EP (2) EP3115371A1 (fr)
JP (1) JP2018524003A (fr)
KR (1) KR20180026755A (fr)
CN (1) CN107849106A (fr)
AR (1) AR105257A1 (fr)
AU (1) AU2016289839A1 (fr)
BR (1) BR112018000155A2 (fr)
CA (1) CA2991298A1 (fr)
CL (1) CL2018000015A1 (fr)
CO (1) CO2018001188A2 (fr)
CR (1) CR20180079A (fr)
DO (1) DOP2018000001A (fr)
EA (1) EA201890234A1 (fr)
EC (1) ECSP18008488A (fr)
HK (1) HK1249110A1 (fr)
IL (1) IL256694A (fr)
MA (1) MA42006A1 (fr)
MX (1) MX2018000206A (fr)
PE (1) PE20180490A1 (fr)
PH (1) PH12018500058A1 (fr)
TN (1) TN2017000547A1 (fr)
TW (1) TW201716435A (fr)
UY (1) UY36772A (fr)
WO (1) WO2017005763A1 (fr)
ZA (1) ZA201708754B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TN2017000348A1 (en) 2015-02-18 2019-01-16 Sanofi Sa Novel proteins specific for pyoverdine and pyochelin
EP3115371A1 (fr) * 2015-07-07 2017-01-11 Sanofi Molécules de fusion
CA3127973A1 (fr) * 2019-03-29 2020-10-08 Pieris Pharmaceuticals Gmbh Administration inhalee de muteines de lipocaline
CN111848734B (zh) * 2020-06-17 2022-04-05 自然资源部第三海洋研究所 一种具有荧光特性的铁载体pvd、制备方法及其用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (fr) 1998-03-31 1999-09-30 Hemosol Inc. Complexes d'amidon hydroxyethyles d'hemoglobine
ATE307597T1 (de) 1998-06-08 2005-11-15 Hoffmann La Roche Verwendung von peg-ifn-alpha und ribavirin zur behandlung chronischer hepatitis c
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
JP4469456B2 (ja) 2000-04-19 2010-05-26 第一三共株式会社 緑膿菌鉄獲得系阻害物質のスクリーニング法
US7211395B2 (en) 2001-03-09 2007-05-01 Dyax Corp. Serum albumin binding moieties
WO2003029462A1 (fr) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteines de la lipocaline neutrophile humaine associee a la gelatinase et de proteines apparentees
US7056702B2 (en) 2002-12-16 2006-06-06 Kimberly Clark Co Detecting lipocalin
WO2006056464A2 (fr) 2004-11-26 2006-06-01 Pieris Ag Compose a affinite pour l'antigene associe au lymphocyte t cytotoxique (ctla-4)
WO2007038619A2 (fr) 2005-09-27 2007-04-05 Amunix, Inc. Produits pharmaceutiques proteiques et utilisations de ceux-ci
DK3381933T3 (da) * 2008-06-24 2020-08-03 Technische Universität München Muteiner af hngal og relaterede proteiner med affinitet til et givet mål
SG10201408073XA (en) 2009-12-07 2015-01-29 Pieris Ag Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target
WO2011149962A1 (fr) * 2010-05-24 2011-12-01 The Trustees Of Columbia University In The City Of New York Proteines ngal mutantes et leurs utilisations
EP2920202B1 (fr) * 2012-11-19 2018-08-29 Pieris Pharmaceuticals GmbH Nouveaux polypeptides se liant specifiquement, et leur utilisation
CN103074303A (zh) * 2012-12-27 2013-05-01 中国人民解放军第三军医大学 产生抗人ngal特异性单克隆抗体的杂交瘤细胞株及其产生的单克隆抗体与应用
TN2017000348A1 (en) 2015-02-18 2019-01-16 Sanofi Sa Novel proteins specific for pyoverdine and pyochelin
EP3298029A1 (fr) 2015-05-18 2018-03-28 Pieris Pharmaceuticals GmbH Mutéines de la lipocaline 2 humaine avec affinité pour glypican-3 (gpc3)
EP3115371A1 (fr) * 2015-07-07 2017-01-11 Sanofi Molécules de fusion

Also Published As

Publication number Publication date
CR20180079A (es) 2018-04-24
WO2017005763A1 (fr) 2017-01-12
KR20180026755A (ko) 2018-03-13
EA201890234A1 (ru) 2018-06-29
AR105257A1 (es) 2017-09-20
UY36772A (es) 2017-01-31
TN2017000547A1 (en) 2019-04-12
MX2018000206A (es) 2018-02-26
EP3319986A1 (fr) 2018-05-16
DOP2018000001A (es) 2018-05-15
AU2016289839A1 (en) 2018-03-01
ECSP18008488A (es) 2018-04-30
JP2018524003A (ja) 2018-08-30
US20170029477A1 (en) 2017-02-02
PH12018500058A1 (en) 2018-07-09
CA2991298A1 (fr) 2017-01-12
US10947284B2 (en) 2021-03-16
US20190382455A1 (en) 2019-12-19
CL2018000015A1 (es) 2018-07-13
BR112018000155A2 (pt) 2018-09-11
CN107849106A (zh) 2018-03-27
PE20180490A1 (es) 2018-03-07
TW201716435A (zh) 2017-05-16
US10316071B2 (en) 2019-06-11
CO2018001188A2 (es) 2018-05-10
EP3115371A1 (fr) 2017-01-11
HK1249110A1 (zh) 2018-10-26
ZA201708754B (en) 2018-11-28
IL256694A (en) 2018-03-29

Similar Documents

Publication Publication Date Title
MA41013A (fr) Compositions comprenant des souches bactériennes
MA41072A1 (fr) Nouvelles protéines spécifiques de la pyoverdine et de la pyochéline
EA201890315A1 (ru) Молекулы антител, связывающие cd22
PH12018501206A1 (en) Antibody molecules to pd-1 and uses thereof
MA42560A (fr) Compositions comprenant des souches bactériennes de blautia pour le traitement de l'hypersensibilité viscérale
EA201890321A1 (ru) Молекулы антител, которые связываются с cd45
EA201890204A1 (ru) Антибактериальные соединения
MA44322A (fr) Compositions comprenant des souches bactériennes
CO7111285A2 (es) Composiciones pesticidas y procesos relacionados con ellas
EA201890320A1 (ru) Молекулы антител, которые связывают cd79
FR3028753B1 (fr) Gel aqueux ou hydroalcoolique de phyllosilicates synthetiques a titre d'agent viscosant, matifiant et/ou homogeneisant d'application
MA38495A1 (fr) Compositions et méthodes pour le diagnostic et le traitement de cancers hépatiques
MA42006A1 (fr) Molécules hybrides
CL2020002468A1 (es) Anticuerpos que se unen a la sortilina e inhiben la union de progranulina.(divisional de solicitud 92-2018)
MX2019004859A (es) Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas.
EA201791174A1 (ru) Антимикотическое соединение
MA46548A (fr) Fsh pour le traitement de l'infertilité
MA38369B1 (fr) Peptides et compositions pour le traitement d'une lesion de l'articulation
IN2014MN01733A (fr)
MA54161A (fr) Compositions comprenant des souches bactériennes parabacteroides pour le traitement du cancer
MA39228A1 (fr) Compositions à utiliser pour le traitement d'états allergiques
GB2564990A8 (en) Topical compositions for neuropathic pain
MA40844A (fr) Compositions pharmaceutiques à action prolongée pour l'hépatite c
FR3038605B1 (fr) Diamines primaires vicinales associees a des motifs chelateurs de metaux et/ou de radicaux libres, actives contre les stress carbonyle et oxydant et leur utilisation
MA39336A1 (fr) Molécules d'anticorps anti-lag-3 et leurs utilisations